Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon-Resistant Chronic Hepatitis C

Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon-Resistant Chronic Hepatitis C

Preliminary reports suggest that patients with interferon (IFN)-resistant chronic hepatitis C respond better to a combination of IFN-α and nonsteroidal anti-inflammatory drugs than to IFN...

Full description

Saved in:

Bibliographic Details
Main Authors:	Frank H Anderson, Lecheng Zeng, Eric M Yoshida, Natalie R Rock
Format:	Article
Language:	English
Published:	Wiley 1997-01-01
Series:	Canadian Journal of Gastroenterology
Online Access:	http://dx.doi.org/10.1155/1997/562402
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pilot Study of Ofloxacin and Interferon-Alpha Combination Therapy for Chronic Hepatitis C without Sustained Response to Initial Interferon Therapy
by: Masafumi Komatsu, et al.
Published: (1997-01-01)

High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C
by: David N Moskovitz, et al.
Published: (2003-01-01)

Acute Hepatitis Induced by Alpha-Interferon in a Patient with Chronic Hepatitis C
by: Ivan Kraus, et al.
Published: (2001-01-01)

Pegilated interferon α2а in treatment of chronic hepatitis C
by: P. O. Bogomolov, et al.
Published: (2012-09-01)

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
by: Eric M Yoshida, et al.
Published: (2009-01-01)

Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-03-01)

Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?
by: S. N. Batskikh
Published: (2014-10-01)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
by: R. Rodríguez-Lojo, et al.
Published: (2010-01-01)

Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C
by: Yvette Leung, et al.
Published: (2006-01-01)

Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01)

Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C
by: N. B. Kovaleva
Published: (2014-08-01)

Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy
by: Bassem Refaat, et al.
Published: (2015-01-01)

Onset of Celiac Disease after Treatment of Chronic Hepatitis C with Interferon Based Triple Therapy
by: Amandeep Singh, et al.
Published: (2015-01-01)

Interferons and Interferon Regulatory Factors in Malaria
by: Sin Yee Gun, et al.
Published: (2014-01-01)

The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy
by: Janina Bruening, et al.
Published: (2017-01-01)

A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C
by: Masafumi Komatsu, et al.
Published: (1997-01-01)

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial)
by: Marina V. Mayevskaya, et al.
Published: (2018-08-01)

Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C
by: Louis WC Liu, et al.
Published: (2003-01-01)

Treatment of Chronic Viral Hepatitis with Alpha-Interferon: A Consensus Conference Report
by: The CASL Hepatitis Consensus Group
Published: (1994-01-01)

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01)

Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection
by: Yong Li, et al.
Published: (2016-01-01)

The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C
by: F. Bellanti, et al.
Published: (2012-01-01)

Interferon Treatment of Hepatitis C Reinfection after Liver Transplantation: A Meta-Analysis
by: Yaqin Chen, et al.
Published: (2015-01-01)

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
by: Dorota Zarębska-Michaluk, et al.
Published: (2019-01-01)

Efficacy and Safety of a Novel Pegylated Interferon Alpha-2a in Egyptian Patients with Genotype 4 Chronic Hepatitis C
by: Alaa Awad Taha, et al.
Published: (2010-01-01)

Restoration of Innate and Adaptive Immune Responses by HCV Viral Inhibition with an Induction Approach Using Natural Interferon-Beta in Chronic Hepatitis C
by: Y. Kishida, et al.
Published: (2012-01-01)

Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen
by: Andrew Trigg, et al.
Published: (2019-02-01)

The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection
by: N. D. Yuschuk, et al.
Published: (2009-02-01)

Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2
by: Naota Taura, et al.
Published: (2012-01-01)

Hepatitis C Virus Clearance after Discontinuation of Pegylated Interferon Alpha-2a Monotherapy in a Child
by: Takeshi Endo, et al.
Published: (2012-01-01)

The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i>
by: A. V. Lapshin, et al.
Published: (2013-03-01)

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study
by: V. T. Ivashkin, et al.
Published: (2014-07-01)

Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus
by: Cecilia T Costiniuk, et al.
Published: (2008-01-01)

Interferon Induced Focal Segmental Glomerulosclerosis
by: Yusuf Kayar, et al.
Published: (2016-01-01)

Evaluation of the microenvironment formed by interferon-β
by: Mai Yamagishi, et al.
Published: (2025-01-01)

Association between Interferon-Inducible Protein 6 () Polymorphisms and Hepatitis B Virus Clearance
by: Geun-Hee Park, et al.
Published: (2013-03-01)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
by: B. Uz, et al.
Published: (2011-01-01)

Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
by: Amr Maged Mahmoud Rasheed, et al.
Published: (2025-02-01)

Early Changes in Hepatitis C Virus (HCV) RNA Levels Predict Response to Interferon Treatment in Non-Cirrhotic HCV Patients
by: Glen Fallows, et al.
Published: (2000-01-01)

Which came first in lupus: The interferon or the infection?
by: T G Sundaram, et al.
Published: (2022-01-01)